Michael Cullen

Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas

Michael Cullen, Neil Steven, Lucinda Billingham et al. · New England Journal of Medicine · 2005 · 423 citations · Full text

Medicine, Oncology, Pharmacology +17

Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study

Lucio Crinò, Federico Cappuzzo, Petr Zatloukal et al. · Journal of Clinical Oncology · 2008 · 217 citations

Medicine, Oncology, Pharmacology +14

Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)

Peter Johnson, John Radford, Michael Cullen et al. · Journal of Clinical Oncology · 2005 · 135 citations · Full text

Medicine, Oncology, Pharmacology +11

P-glycoprotein possesses A 1,4-dihydropyridine-selective drug acceptor site which is alloserically coupled to a vinca-alkaloid-selective binding site

David R. Ferry, Michael A. Russell, Michael Cullen · Biochemical and Biophysical Research Communications · 1992 · 125 citations

Medicine, Medicinal Chemistry, Pharmacology +10

Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR)

Michael J. Seckl, Christian H. Ottensmeier, Michael Cullen et al. · Journal of Clinical Oncology · 2017 · 113 citations · Full text

Medicine, Oncology, Pharmacology +13